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Establishing and strengthening pharmacovigilance in
resource-limited settings provides a valuable opportunity
to identify, quantify and address pertinent safety concerns
regarding the use of single low-dose (SLD) primaquine.
While it is understood that primaquine causes dose-
dependent hemolysis in glucose-6-phosphate dehydrogen-
ase (G6PD) deficient individuals with P. falciparum and
P. vivax malaria, the extent of this risk when using low
doses of primaquine remains to be defined. Prospective
pharmacovigilance methods are needed to confirm or
refute these safety concerns that have likely hindered the
uptake of the new WHO policy for SLD primaquine.
Pharmacovigilance in resource-limited settings is chal-
lenging, especially when attempting to identify unknown
or poorly understood adverse drug reactions over weeks of
follow-up. In contrast, the objectives of a pharmacovigi-
lance program for SLD primaquine are specific, measur-
able, and attainable within a short time frame. The nadir
of primaquine-induced hemolytic anemia, measurable by
hemoglobin concentrations, has been shown to occur on
or near day 7. Thus, it is expected that adverse drug reac-
tions related to primaquine can be captured within a week
of drug administration by active surveillance methods
involving patient follow-up. Furthermore, dark urine is a
characteristic sign of acute hemolytic anemia, an easily
identifiable and documentable symptom of hemolysis.
Numerous pharmacovigilance efforts are ongoing, sup-
porting individual countries in the collection of standar-
dized SLD primaquine safety data. These efforts seek to
establish the expected fall in hemoglobin from baseline
levels before treatment to levels seven days post-treat-
ment and include G6PD testing and recording of adverse
events using standard data collection instruments. Each
participating in-country program or study site aims to
collect data on 100-400 subjects depending on malaria
endemicity and expected G6PD prevalence. We plan to
collate data across these countries in a global database of
individual patient data, contributing to the evidence-base
for benefit-risk assessments of SLD primaquine.
As other 8-aminoquinoline drugs such as tafenoquine
come to market, we will be faced with related safety con-
cerns of dose-dependent hemolysis in G6PD-deficient
individuals. Active pharmacovigilance and the establish-
ment of a standardized database for SLD primaquine not
only provide opportunities to harmonize efforts, address
unanswered questions regarding the safe use of SLD
primaquine, and assist programs planning widespread roll-
out of SLD primaquine in routine malaria case manage-
ment they can also serve as a common platform for other
current and future pharmacovigilance needs. The methods
used in these efforts and the composition of this database
will be described.
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